Biologic Monotherapies for Moderate-to-Severe Atopic Dermatitis: A Systematic Review and Bayesian Network Meta-Analysis of Established and Investigational Agents - PubMed
5 hours ago
- #Biologic Therapy
- #Network Meta-Analysis
- #Atopic Dermatitis
- Systematic review and Bayesian network meta-analysis (BNMA) compared biologic monotherapies for moderate-to-severe atopic dermatitis.
- Dupilumab demonstrated the most consistent and reliable efficacy across endpoints like EASI-75, EASI-90, IGA-AD 0/1, and itch NRS.
- Among investigational therapies, rocatinlimab showed notable signals for deep clinical responses, but evidence was limited.
- Other emerging agents (rademikibart, temtokibart, zumilokibart) had encouraging efficacy, while telazorlimab showed modest benefit.
- Treatment rankings (SUCRA/P-score) positioned dupilumab as the highest-performing therapy overall, followed by rocatinlimab.
- Biologic therapies were generally well-tolerated short-term, but only dupilumab had extensive long-term safety data (up to a decade).
- Limitations included reliance on indirect comparisons, short-term data, trial heterogeneity, and wide credible intervals for newer agents.
- Findings provide a comparative framework to guide biologic selection and therapeutic sequencing in clinical practice.